Healthcare Stocks Review : Best Stocks For 2013

AEterna Zentaris, Inc. could be a late-stage drug development company, that makes a specialty of medical specialty and endocrine medical care. The corporate investigates treatments for varied cancers which incorporates body part, myeloma, mucous membrane, ovarian, bladder cancer and prostate. Its pipeline encompasses compounds in the least stages of development from drug discovery through marketing product. The corporate focus on the event of perifosine, AEZS-108 and AEZS-130. AEterna Zentaris was supported on Sep twelve, 1990 and is located in Quebec, Canada. 

Is AEZS A Secure Investment At This Level? Watch Out An Over View of INFI Here

AEterna Zentaris (NASDAQ:AEZS) reported  EPS of -1.169. For this year, the corporation is predicted to report EPS of -0.90. For consequent Quarter and Next Season, the business is expected to review EPS of -0.32 and -1.11 severally. At Current value, AEZS is in the distance of +13.58% from its 50-day Moving Average value of $2.1747 and -9.72% from its 200-day Moving Average value of $2.7358.

Aeterna Zentaris (NASDAQ:AEZS) has reached AN agreement with the FDA on a Special Protocol Assessment for a future part three registration trial in carcinoma with its antibiotic amide conjugate, AEZS-108. The accord states that the planned trial protocol style, clinical endpoints and planned analyses are all acceptable to the authority in support of a restrictive submission. AEZS-108 represents a replacement targeting conception in medical specialty employing a hybrid molecule composed of an artificial amide carrier and a widely known therapeutic agent, antibiotic. AEZS-108 is that the 1st Endovenous drug in advanced clinical development that directs the therapeutic agent specifically to interstitial cell-stimulating hormone cathartic endocrine (LHRH)-receptor expressing tumors, leading to a lot of targeted treatment with less harm to healthy tissue. The merchandise has with success completed part a pair of studies for the treatment of female internal reproductive organ and carcinoma and also the Company are presently designing a part three trial in carcinoma below a Special Protocol Assessment.